Literature DB >> 27432512

Safety and Effectiveness of Drip, Ship, and Retrieve Paradigm for Acute Ischemic Stroke: a Single Center Experience.

Nagayasu Hiyama1, Shinichi Yoshimura, Manabu Shirakawa, Kazutaka Uchida, Yoshiharu Oki, Seigo Shindo, Kou Tokuda.   

Abstract

This study analyzed the efficacy and safety of the "drip, ship, and retrieve (DSR)" approach used to improve patient access to thrombectomy for acute stroke.
METHODS: The study participants were 45 patients who underwent thrombectomy following intravenous tissue plasminogen activator between September 2013 and August 2015. Patients were divided into two groups according to whether they were transferred from another hospital (DSR group; n = 33) or were brought in directly (Direct group; n = 12). The two groups were compared based on their baseline characteristics, time from stroke onset to reperfusion, outcome, and adverse events.
RESULTS: There were no significant differences in baseline characteristics. Time from onset until admission to our facility was significantly shorter in the Direct group (56.9 min) than in the DSR group (163.5 min) (P <0.0001). Conversely, time from arrival at the hospital to arterial puncture was significantly shorter in the DSR group (25.0 min) than in the Direct group (109.5 min) (P <0.0001). Time from onset to reperfusion did not differ significantly between the groups. There was no significant difference in patient outcomes, with a modified Rankin scale score of 0-2 (44.8% in DSR group versus 48.7% in Direct group). Moreover, there was no difference in the incidence of adverse events. DISCUSSION: Despite the time required to transfer patients in the DSR group between hospitals, reducing the time from arrival until commencement of endovascular therapy meant that the time from onset to reperfusion was approximately equivalent to that of the Direct group.
CONCLUSION: Time-saving measures need to be taken by both the transferring and receiving hospitals in DSR paradigm.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27432512      PMCID: PMC5221770          DOI: 10.2176/nmc.oa.2016-0102

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


Introduction

Endovascular thrombectomy is indicated in Japan for acute ischemic stroke due to large vessel occlusion where tissue plasminogen activator (t-PA) is either not indicated or ineffective. Until recently, however, there was no evidence attesting to the efficacy of this procedure. This changed in 2015 with the announcement of findings from 5 randomized, controlled trials (RCTs)[1–5)] demonstrating the efficacy of endovascular thrombectomy. The U.S. Guidelines on early endovascular treatment of acute ischemic stroke have also been modified, with the 2015 Focused Update by the American Heart Association/American Stroke Association (AHA/ASA) now recommending the use of endovascular therapy with a stent retriever in patients who meet all of the following 6 criteria (Class I; Level of Evidence A): (a) prestroke modified Rankin scale (mRS) score 0 to 1; (b) receiving intravenous t-PA within 4.5 hours of stroke onset; (c) causative occlusion of the internal carotid artery or proximal MCA (M1); (d) age ≥18 years; (e) National Institute of Health Stroke Scale (NIHSS) score of ≥6; (f) Alberta Stroke Program Early CT score (ASPECTS) of ≥6; and (g) treatment can be initiated within 6 hours of symptom onset.[6)] In Japan, however, there are limitations on the number of facilities that can perform this procedure on a permanent basis and on the types of patients that can undergo it. Pfefferkorn et al. proposed a treatment protocol to transfer acute stroke patients to a facility capable of performing thrombectomy. The authors referred to this protocol as “drip, ship, and retrieve” (DSR) based on the steps of administering intravenous t-PA (“drip”), transferring the patient (“ship”), and retrieving the thrombus (“retrieve”).[7)] This cooperative protocol offers the advantage of increased patient access to thrombectomy, but it also has the disadvantage of being time-consuming compared to the direct transport of patients to a thrombectomy-capable facility. For this reason, transferred patients reportedly have poor outcomes compared to those who are transported directly.[8)] Initiatives to reduce the time spent at the transferring facility and the time until starting endovascular therapy at the receiving facility are therefore essential when transferring acute stroke patients. In the present study, the efficacy and safety of DSR were analyzed by comparing patients treated with this approach and patients transported directly.

Materials and Methods

The study participants were 45 patients who underwent thrombectomy following intravenous t-PA at our hospital between September 2013 and August 2015. During this period, 41 patients were transferred to our hospital via drip and ship paradigm, and 33 received thrombectomy (80.5%). In this study, the patients treated by thrombectomy were divided into two groups according to whether they were transferred from another hospital (DSR group; n = 33) or were brought in directly (Direct group; n = 12). Patient demographic and baseline characteristics including age, sex, past medical history, severity of neurological deficit (NIHSS score), and extent of the stroke on CT imaging (ASPECTS) were compared between the two groups. Other compared variables were the recanalization rate based on the Thrombolysis in Cerebral Infarction (TICI) grade, modified Rankin scale (mRS) score at 3 months post-treatment, and adverse event incidence. Compared variables related to treatment time were time from stroke onset to reperfusion, time to diagnostic imaging, time from diagnostic imaging to t-PA administration, time from arrival at the receiving facility until the arterial puncture, and time from an arterial puncture to reperfusion.

Magnetic Resonance Imaging (MRI)

All included patients underwent MRI (1.5 Tesla, Intera Achieva Pulsar; Philips, Amsterdam, NED). Images included diffusion-weighted imaging (DWI), axial fluid-attenuated inversion recovery, 3-dimensional time-of-flight magnetic resonance angiography. DWI was performed using echo planar imaging techniques. The DWI lesion volume was determined by manually tracing the edge of the hyperintense signal on each slice of the trace DWI scans. DWI–the Alberta Stroke Program Early Computed Tomography Score (DWI-ASPECTS)[9)] on admission was assessed by stroke specialist.

Endovascular Therapy (EVT)

Patients without significant reperfusion on cerebral angiography after receiving t-PA underwent endovascular treatment using a suction catheter (Penumbra system, Penumbra, Alameda, CA, USA) or stent retriever (Solitaire FR, Medtronic Neurovascular, Irvine, CA, USA; Trevo ProVue, Stryker Neurovascular, Fremont, CA, USA) under local anesthesia.

Evaluation of Clinical Outcomes

Patient outcomes were evaluated using the mRS score at 90 (±10) days after onset. Favorable outcomes were defined as mRS scores of 0–2.

Results

There were no significant differences between the groups in any of the patient demographic or baseline characteristics (Table 1).
Table 1

Baseline characteristics of the patients treated by thrombectomy via drip and ship or direct transfer

Baseline characteristicsDSR (n = 33)Direct (n = 12)P
age–yr
Median74.2 (66–82)78(67–86)0.92
Female sex–no.(%)12 (36.4)8 (66.7)0.69
Medical history–no.(%)
  Atrial fibrillation21 (63.6)10 (83.3)0.20
  Diabetes Mellitus6 (18.2)0 (0)0.11
  Hypertension18 (30.3)6 (50)0.78
modified Rankin Scale–no.(%)
  027 (81.8)8 (66.7)0.47
  11 (3)0 (0)
  21 (3)1 (8.3)
  3–54 (12.1)3 (25)0.48
NIHSS*
  Median(Interquartile range)18 (15–26)22 (15–27)
  Range5–405–400.44
ASPECTS**
  median(Interquartile range)7(5–8)8 (7–9)0.48
Site of occlusion–no.(%)
  Internal Carotid Artery15 (45.5)1 (8.3)0.012
  Middle Cerebral Artery14 (42.4)10 (83.3)0.011
  Basilar Artery4 (12.1)1 (8.3)0.53

ASPECTS, Alberta Stroke Program Early CT score; NIHSS, National Institute Health Stroke Scale.

Time from onset until admission to our facility was significantly shorter in the Direct group (56.9 min) than in the DSR group (163.5 min) (P <0.0001). Conversely, time from arrival at the hospital to arterial puncture was significantly shorter in the DSR group (25.0 min) than in the Direct group (109.5 min) (P <0.0001). Time from stroke onset to reperfusion did not differ significantly between the DSR group (268.0 min) and the Direct group (244.5 min) (Table 2, Fig. 1).
Table 2

Time metrics from stroke onset to reperfusion

Process measures (min)DSRDirectP
Onset to door163.5 (54.0–344.0)56.9 (26.0–161.0)<0.0001
Door to puncture25.0 (16.3–27.8)109.5 (61.8–159.5)<0.0001
Onset to reperfusion268.0 (224.0–330.0)244.5 (186.5–267.3)0.21
Fig. 1

Comparison of time metrics of the acute stroke patients in the Drip, Ship and Retrieve (DSR) group and Direct group. Time from onset until admission to our facility is significantly shorter in the Direct group (56.9 min) than in the DSR group (163.5 min). Conversely, time from arrival at the hospital to arterial puncture is significantly shorter in the DSR group (25.0 min) than in the Direct group (109.5 min). Time from onset to reperfusion does not differ significantly between the DSR group (268.0 min) and the Direct group (244.5 min).

Significant reperfusion (TICI 2b-3) was achieved in 30 of 33 patients (90.9%) in the DSR group and 11 of 12 patients (91.7%) in the Direct group. There was no significant difference between the groups in the percentage of favorable outcomes (mRS score 0-2) (odds ratio: 0.92, 95% confidence interval: 0.20-4.17) (Fig. 2). There was also no difference in the incidence of adverse events such as intracranial hemorrhage and procedure-related complications. Two patients in the DSR group required decompressive craniectomy. There was one death in DSR group and two in Direct group; there was no significant difference in mortality (Table 3). No adverse events occurred in the DSR group during transfer.
Fig. 2

Comparison of clinical outcomes of the acute stroke patients in the DSR group and Direct group.

Table 3

Adverse events

Event–no.(%)DSRDirectP
Death1 (3%)2 (16.7%)0.13
Hemorrhagic transformation (total)12 (36.4%)4 (33.3%)0.79
  Hemorrhagic infarction9 (3%)4 (33.3%)0.69
  Parenchymal hematoma3 (9%)0 (0%)0.47
Symptomatic hemorrhage1 (3%)1 (8.3%)0.16
Intraoperative adverse events (total)2 (6%)1 (8.3%)0.79
  Perforation of the intracranial artery1 (3%)0 (0%)0.42
  Embolization in new territory1 (3%)1 (8.3%)0.48
Decompressive hemicraniectomy2 (6%)0 (0%)0.25

Discussion

In the DSR approach used in the present study, the time taken to transfer DSR group patients after intravenous t-PA significantly prolonged their time from stroke onset until admission to our hospital. However, our efforts to reduce the time from their arrival until commencement of thrombectomy meant that the time from stroke onset to reperfusion was almost equivalent to that of the Direct group. There were also no significant differences between the groups in terms of patient outcomes and adverse events, suggesting that the DSR approach is both safe and effective. There is a considerable amount of literature pointing to the safety and efficacy of transfer-based treatment of acute stroke patients. A study by Sheth et al. analyzing data from 44,667 patients with ischemic stroke treated with IV t-PA in the U.S. reported that drip and ship (D&S) was performed in 10,475 (23.5%) of these patients.[10)] Tekle et al. used a U.S. database of insured medical care to compare the data from 22,243 acute ischemic stroke patients transported directly to the hospital with the data of 4,474 patients treated by the D&S method, and they found that the rate of in-hospital death was lower and the rate of home discharge/self-care was higher in the D&S group.[11)] On the other hand, previous studies have also highlighted the issues surrounding the D&S approach, such as the pronounced trend towards symptomatic intracranial hemorrhage in the D&S group reported by Sheth et al. Moreover, a study in South Korea comparing the data from 78 D&S patients with that of 317 directly-transported patients found that the percentage of poor prognosis cases (mRS score of 3-6 at 90 days post-treatment) was higher in the D&S group.[8)] The results of analysis in these studies indicated that hospital transfers delayed the initiation of treatment, suggesting the need to implement time-saving measures. Meanwhile, in the study by Tekle et al., “retrieve” procedures only accounted for 4,474 patients—just 7%—of the entire study population,[11)] so this study can hardly be described as an analysis of DSR. On the other hand, the present study differs to that of previous literature in that it was concerned solely with the analysis of DSR patients. As such, the present study is the first of its kind to investigate the safety and efficacy of the DSR approach since the introduction of the stent retriever. Since thrombectomy is currently known to be an effective stroke treatment, improving its rate of adoption is a pressing issue. However, there are limitations on the number of facilities in Japan that can perform thrombectomy 24 hours a day and on the types of patients that can undergo this procedure. Under these circumstances, the DSR approach could help to improve the rate of thrombectomy procedures. However, increases in hospital transfer times can prolong the time to reperfusion, suggesting that significant improvements in prognosis may not be feasible even when reperfusion is achieved with thrombectomy. Sudden changes in the patient’s condition during transfer can lead to deterioration of outcomes, while the failure of the initial treating physician to accompany patients being treated with the DSR approach can also lead to worsening of symptoms during transport. Accordingly, when implementing the DSR approach, measures to reduce the additional time of transfer are essential for improving patient prognosis. In the present study, there was no difference between DSR and directly-transported patients in the time to commencement of endovascular therapy as a result of reductions in the time spent at the transferring hospital and the time until the commencement of endovascular treatment at the receiving hospital. These time-saving measures require the expedited sharing of data on tests performed at the transferring hospital with the receiving hospital. The recent use of information and communication technology (ICT) between transferring and receiving facilities has enabled real-time transmission of CT, MRI, and other imaging data. In the U.S., the use of specialized telemedicine systems for exchanging information on stroke patients is known as “telestroke”. As of 2012, there were 38 telestroke programs operating in 27 states.[12)] A study by Yaghir et al. reported a high rate of good treatment outcomes in transferred stroke patients treated with the aid of a telestroke program, suggesting the efficacy of this form of telemedicine.[13)] However, there have also been issues associated with this technology, as shown by a study which found that 23% of patients diagnosed via telemedicine were in fact stroke mimics.[14)] There were no stroke mimics in the present study because the initial diagnosis was performed directly by a stroke specialist. However, the occurrence of stroke mimics could increase in the future with the spread of ICT. While none of the patients in our study experienced sudden changes or adverse events during transfer, it is crucial for the physician to accompany and constantly monitor the patient. The limitations of this study include the retrospective nature of the analyses and the limited study population. The analyses were also limited to the DSR protocol of a single transferring hospital, so a prospective study of multiple facilities should be conducted in the future. A large-scale prospective study with the aim of clarifying the efficacy and issues of the DSR approach is essential given that this coordinated approach will be indispensable for enabling increased access to thrombectomy among stroke patients in Japan.

Conclusion

The study findings suggest that time-saving initiatives adopted by transferring and receiving hospitals can reduce the time to reperfusion among DSR patients to approximately that of directly-transported patients.
  14 in total

1.  Drip-and-ship thrombolytic treatment paradigm among acute ischemic stroke patients in the United States.

Authors:  Wondwossen G Tekle; Saqib A Chaudhry; Ameer E Hassan; Gustavo J Rodriguez; M Fareed K Suri; Adnan I Qureshi
Journal:  Stroke       Date:  2012-06-05       Impact factor: 7.914

2.  The status of telestroke in the United States: a survey of currently active stroke telemedicine programs.

Authors:  Gisele S Silva; Shawn Farrell; Emma Shandra; Anand Viswanathan; Lee H Schwamm
Journal:  Stroke       Date:  2012-06-14       Impact factor: 7.914

3.  Post t-PA transfer to hub improves outcome of moderate to severe ischemic stroke patients.

Authors:  Shadi Yaghi; Sami I Harik; Archana Hinduja; Nicolas Bianchi; Debra M Johnson; Salah G Keyrouz
Journal:  J Telemed Telecare       Date:  2015-05-10       Impact factor: 6.184

4.  Outcomes after tissue plasminogen activator administration under the drip and ship paradigm may differ according to the regional stroke care system.

Authors:  Jae-Kwan Cha; Hyun-Wook Nah; Myung-Jin Kang; Dae-Hyun Kim; Hyun-Seok Park; Sang-Beom Kim; Eun Hwan Jeong; Jae-Taeck Huh
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-10-21       Impact factor: 2.136

5.  Endovascular therapy for ischemic stroke with perfusion-imaging selection.

Authors:  Bruce C V Campbell; Peter J Mitchell; Timothy J Kleinig; Helen M Dewey; Leonid Churilov; Nawaf Yassi; Bernard Yan; Richard J Dowling; Mark W Parsons; Thomas J Oxley; Teddy Y Wu; Mark Brooks; Marion A Simpson; Ferdinand Miteff; Christopher R Levi; Martin Krause; Timothy J Harrington; Kenneth C Faulder; Brendan S Steinfort; Miriam Priglinger; Timothy Ang; Rebecca Scroop; P Alan Barber; Ben McGuinness; Tissa Wijeratne; Thanh G Phan; Winston Chong; Ronil V Chandra; Christopher F Bladin; Monica Badve; Henry Rice; Laetitia de Villiers; Henry Ma; Patricia M Desmond; Geoffrey A Donnan; Stephen M Davis
Journal:  N Engl J Med       Date:  2015-02-11       Impact factor: 91.245

6.  Drip and ship thrombolytic therapy for acute ischemic stroke: use, temporal trends, and outcomes.

Authors:  Kevin N Sheth; Eric E Smith; Maria V Grau-Sepulveda; Dawn Kleindorfer; Gregg C Fonarow; Lee H Schwamm
Journal:  Stroke       Date:  2015-02-11       Impact factor: 7.914

7.  A randomized trial of intraarterial treatment for acute ischemic stroke.

Authors:  Olvert A Berkhemer; Puck S S Fransen; Debbie Beumer; Lucie A van den Berg; Hester F Lingsma; Albert J Yoo; Wouter J Schonewille; Jan Albert Vos; Paul J Nederkoorn; Marieke J H Wermer; Marianne A A van Walderveen; Julie Staals; Jeannette Hofmeijer; Jacques A van Oostayen; Geert J Lycklama à Nijeholt; Jelis Boiten; Patrick A Brouwer; Bart J Emmer; Sebastiaan F de Bruijn; Lukas C van Dijk; L Jaap Kappelle; Rob H Lo; Ewoud J van Dijk; Joost de Vries; Paul L M de Kort; Willem Jan J van Rooij; Jan S P van den Berg; Boudewijn A A M van Hasselt; Leo A M Aerden; René J Dallinga; Marieke C Visser; Joseph C J Bot; Patrick C Vroomen; Omid Eshghi; Tobien H C M L Schreuder; Roel J J Heijboer; Koos Keizer; Alexander V Tielbeek; Heleen M den Hertog; Dick G Gerrits; Renske M van den Berg-Vos; Giorgos B Karas; Ewout W Steyerberg; H Zwenneke Flach; Henk A Marquering; Marieke E S Sprengers; Sjoerd F M Jenniskens; Ludo F M Beenen; René van den Berg; Peter J Koudstaal; Wim H van Zwam; Yvo B W E M Roos; Aad van der Lugt; Robert J van Oostenbrugge; Charles B L M Majoie; Diederik W J Dippel
Journal:  N Engl J Med       Date:  2014-12-17       Impact factor: 91.245

8.  DWI-ASPECTS as a predictor of dramatic recovery after intravenous recombinant tissue plasminogen activator administration in patients with middle cerebral artery occlusion.

Authors:  Junya Aoki; Kazumi Kimura; Kensaku Shibazaki; Yuki Sakamoto
Journal:  Stroke       Date:  2012-12-04       Impact factor: 7.914

9.  2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.

Authors:  William J Powers; Colin P Derdeyn; José Biller; Christopher S Coffey; Brian L Hoh; Edward C Jauch; Karen C Johnston; S Claiborne Johnston; Alexander A Khalessi; Chelsea S Kidwell; James F Meschia; Bruce Ovbiagele; Dileep R Yavagal
Journal:  Stroke       Date:  2015-06-29       Impact factor: 10.170

10.  Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.

Authors:  Jeffrey L Saver; Mayank Goyal; Alain Bonafe; Hans-Christoph Diener; Elad I Levy; Vitor M Pereira; Gregory W Albers; Christophe Cognard; David J Cohen; Werner Hacke; Olav Jansen; Tudor G Jovin; Heinrich P Mattle; Raul G Nogueira; Adnan H Siddiqui; Dileep R Yavagal; Thomas G Devlin; Demetrius K Lopes; Vivek Reddy; Richard du Mesnil de Rochemont; Reza Jahan
Journal:  Int J Stroke       Date:  2015-04       Impact factor: 5.266

View more
  3 in total

1.  Two Paradigms for Endovascular Thrombectomy After Intravenous Thrombolysis for Acute Ischemic Stroke.

Authors:  Gaspard Gerschenfeld; Ioan-Paul Muresan; Raphael Blanc; Michael Obadia; Marie Abrivard; Michel Piotin; Sonia Alamowitch
Journal:  JAMA Neurol       Date:  2017-05-01       Impact factor: 18.302

Review 2.  Stroke Transfer and its Organizational Paradigm : Review of Organizational Paradigms and the Impact on Outcome.

Authors:  Lili Détraz; Marielle Ernst; Romain Bourcier
Journal:  Clin Neuroradiol       Date:  2018-08-08       Impact factor: 3.649

3.  Efficacy of the Drip and Ship Method in 24-h Helicopter Transportation and Teleradiology for Isolated Islands.

Authors:  Takeshi Hiu; Keisuke Ozono; Ichiro Kawahara; Kazumi Yamasaki; Kei Satoh; Hiroaki Otsuka; Chikaaki Nakamichi; Hiroshi Iwanaga; Yutaka Fukuda; Kazuya Honda; Hiroyuki Hiu; Tomonori Ono; Wataru Haraguchi; Ryujiro Ushijima; Keisuke Tsutsumi
Journal:  Neurol Med Chir (Tokyo)       Date:  2019-11-21       Impact factor: 1.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.